ARGX vs JNJ

For growth investors, argenx SE (ARGX) is the stronger pick with 78.

6% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Johnson & Johnson (JNJ) offers the better valuation at 38. 8x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate argenx SE (ARGX) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Johnson & Johnson (JNJ) is the cheapest at 38.

8x versus argenx SE at 63. 2x. On forward P/E, Johnson & Johnson is actually cheaper at 19. 4x.

Over the past 5 years, argenx SE (ARGX) delivered a total return of +212.

7%, compared to +48. 0% for Johnson & Johnson (JNJ). Over 10 years, the gap is even starker: ARGX returned +34. 1% versus JNJ's +136. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus argenx SE's 0. 52β — meaning ARGX is approximately 821% more volatile than JNJ relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), argenx SE (ARGX) is pulling ahead at 78.

6% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: argenx SE grew EPS 347. 7% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, ARGX leads at 63. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

argenx SE (ARGX) is the more profitable company, earning 38.

0% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 38. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -1. 0% for ARGX. At the gross margin level — before operating expenses — ARGX leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Johnson & Johnson (JNJ) trades at 19.

4x forward P/E versus 30. 7x for argenx SE — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARGX: 30. 3% to $1052. 30.

In this comparison, JNJ (2.

2% yield) pays a dividend. ARGX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, ARGX: +34. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARGX is a mid-cap high-growth stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while ARGX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.